You are here

Subscribe to Ροή
Ενημερώθηκε: πριν από 1 ώρα 50 λεπτά


Τετ, 11/10/2017 - 07:05

Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature.

Categories: ScienceCountries: United States of AmericaLanguages: English